These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24911076)

  • 1. A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization.
    Manko J; Walter-Croneck A; Jawniak D; Grzasko N; Gorska-Kosicka M; Cioch M; Dmoszynska A
    Pharmacol Rep; 2014 Apr; 66(2):239-42. PubMed ID: 24911076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
    Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
    Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.
    Reményi P; Gopcsa L; Marton I; Réti M; Mikala G; Pető M; Barta A; Bátai A; Farkas Z; Borbényi Z; Csukly Z; Bodó I; Fábián J; Király A; Lengyel L; Piukovics K; Torbágyi E; Masszi T
    Adv Ther; 2014 Apr; 31(4):451-60. PubMed ID: 24687301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
    Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
    Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF.
    Schmitt M; Hoffmann JM; Lorenz K; Publicover A; Schmitt A; Nagler A
    Vox Sang; 2016 Aug; 111(2):178-86. PubMed ID: 27509033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation.
    Schmitt M; Publicover A; Orchard KH; Görlach M; Wang L; Schmitt A; Mani J; Tsirigotis P; Kuriakose R; Nagler A
    Theranostics; 2014; 4(3):280-9. PubMed ID: 24505236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
    Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
    Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study.
    Kayıkçı Ö; Tekgündüz E; Kaya AH; Göker H; Aslan A; İskender D; Namdaroglu S; Tetik A; Koçubaba Ş; Altuntaş F
    Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption.
    Aggarwal V; Sabry W; Elemary M; Bosch M; Danyluk P; Mondal P; Stakiw J
    Curr Oncol; 2021 Apr; 28(3):1571-1580. PubMed ID: 33922026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience.
    Islami MM; Khan MA; Aseeri MA; Alshamrani MA; Alnatsheh A; Alamoudi S; Alzahrani AA
    Ann Transplant; 2023 Mar; 28():e938585. PubMed ID: 36864713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
    Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.
    Cesaro S; Tridello G; Prete A; Dallorso S; Cannata E; Massaccesi E; Risso M; De Bortoli M; Caselli D
    Transfusion; 2015 Feb; 55(2):246-52. PubMed ID: 25070657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
    Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study on high-dose etoposide with granulocyte colony-stimulating factor for mobilization of autologous peripheral blood stem cells in patients with hematologic malignancies].
    Shen WY; Li JY; Hong M; Zhang R; Lu H; Liu P; Qian SX; Xu W; Qiu HX; Wu HX
    Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):628-31. PubMed ID: 23134856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
    J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.
    Becker P; Schwebig A; Brauninger S; Bialleck H; Luxembourg B; Schulz M; Tsamadou C; Wiesneth M; Reinhardt P; Mytilineos J; Seidl C; Gattu S; Kaliakina N; Singh P; Schrezenmeier H; Seifried E; Bonig H
    Transfusion; 2016 Dec; 56(12):3055-3064. PubMed ID: 27633122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.
    Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P
    J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
    Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
    J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.